IGM Biosciences, Inc.
NASDAQ:IGMS
16.03 (USD) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 2.13 | 1.069 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 8.277 | 10.602 | 7.724 | 3.576 | 2.333 | 0.278 | 0.161 |
| Gross Profit
| -6.147 | -9.533 | -7.724 | -3.576 | -2.333 | -0.278 | -0.161 |
| Gross Profit Ratio
| -2.886 | -8.918 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 207.242 | 179.289 | 127.026 | 65.03 | 35.257 | 18.962 | 8.639 |
| General & Administrative Expenses
| 50.072 | 49.736 | 38.297 | 18.25 | 9.241 | 3.829 | 2.508 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 50.072 | 49.736 | 38.297 | 18.25 | 9.241 | 3.829 | 2.508 |
| Other Expenses
| -0.02 | -0.181 | 0.159 | 1.925 | 1.365 | 0.08 | 0.093 |
| Operating Expenses
| 257.314 | 229.025 | 165.323 | 83.28 | 44.498 | 22.791 | 11.147 |
| Operating Income
| -263.461 | -227.956 | -165.323 | -83.28 | -44.498 | -22.791 | -11.147 |
| Operating Income Ratio
| -123.691 | -213.242 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 17.723 | 6.854 | 0.159 | 1.925 | 1.365 | 0.08 | 0.093 |
| Income Before Tax
| -245.738 | -221.102 | -165.164 | -81.355 | -43.133 | -22.711 | -11.054 |
| Income Before Tax Ratio
| -115.37 | -206.831 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.678 | -6.854 | -4.484 | -1.025 | -0.597 | 0.08 | 0 |
| Net Income
| -246.416 | -214.248 | -160.68 | -80.33 | -42.536 | -22.711 | -11.054 |
| Net Income Ratio
| -115.688 | -200.419 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -4.71 | -5.16 | -4.8 | -2.61 | -4.73 | -51.84 | -25.24 |
| EPS Diluted
| -4.71 | -5.16 | -4.8 | -2.61 | -4.73 | -51.84 | -25.24 |
| EBITDA
| -255.184 | -227.956 | -165.323 | -83.28 | -44.498 | -22.513 | -10.986 |
| EBITDA Ratio
| -119.805 | -213.242 | 0 | 0 | 0 | 0 | 0 |